The Pentad Framework: A Systematic Review and Conceptual Model for Systems-Level Cardiac Bioprinting

Abstract

Heart transplantation remains the sole definitive cure for end-stage heart failure, yet its clinical application is severely constrained by an acute shortage of donor organs. 3D bioprinting has emerged as a transformative biofabrication paradigm capable of engineering patient-specific cardiac tissue; the transition from in vitro tissue constructs to a clinically transplantable, full-scale bioengineered human heart, though, presents interdisciplinary hurdles that no single technology has yet resolved. This systematic review critically evaluates the extent to which structural limitations in bioink formulations, multi-scale microvascular network integration, and immature electromechanical properties hinder organ-level translation. Current natural, synthetic, and conductive bioinks struggle to reconcile mechanical stiffness (E = 10-15 kPa diastolic, >50 kPa systolic) with bioactivity, and degrade faster than clinical use would allow. Establishing fluidic continuity between macro-conduits (>100 μm) and capillary beds (<10 μm) remains a primary bottleneck in its own right, leaving deep-tissue constructs vulnerable to core hypoxia regardless of how well either scale is engineered in isolation. At the cellular level, human induced pluripotent stem cell-derived cardiomyocytes exhibit fetal-like contraction forces (1-5 mN/mm²) and reduced conduction velocities (10-25 cm/s), both well below adult physiological standards (≥20 mN/mm² and ≥60 cm/s, respectively). To move past the failure of isolated, modular optimization, we introduce the Pentad Integration Framework, a systems-engineering design matrix that unifies bioink mechanics, vascular perfusion, electromechanical coupling, autonomic innervation, and immunological compatibility into a single interdependent model. Addressing whether emerging technologies can close these gaps within a clinically realistic timeframe, our synthesis reveals a phased translational roadmap: 4D bioprinting built on dynamic, stimuli-responsive smart bioinks, and AI-driven predictive modeling are already accelerating biofabrication workflows, while a fully functional, bioengineered whole heart for human transplantation remains a longer-term milestone, requiring 20 to 30+ years given the scale of the cell-scaling requirement alone (2-4 × 10⁹ cardiomyocytes) and the regulatory pathway a whole-organ product would need to clear. Intermediate interventions epicardial patches and bioengineered ventricular assist constructs- sit on a nearer horizon, positioned for clinical deployment within 5 to 15 years and laying the biological and engineering groundwork that complete organ replacement will eventually depend on.